Skip to main content
| News

Novaremed secures US$50 million

03.02.2021

Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to progress the clinical development of its treatment for painful diabetic peripheral neuropathy.

The Luxembourg-based investment group GEM Global Yield has committed to provide Novaremed with up to US$50 million over a 36-month term. In return, GEM will have the right to purchase shares of Novaremed following the public listing of the company, as was explained in a press release from the Basel biotech. Novaremed will control the timing and maximum amount of drawdown under this share subscription facility.

“This funding agreement with GEM will help us, upon the company’s public listing, to advance our highly innovative lead product that we are developing for the non-opioid treatment of patients affected by diabetes-related chronic neuropathic pain,” said Isaac Kobrin, Executive Chairman of the Board of Novaremed, in the press release. His company was founded in Israel in 2008 and set up in Basel at the end of 2017. Basel Area Business & Innovation, the investment and innovation promotion agency, supported Novaremed in making the move.

Novaremed’s lead product, NRD135S.E1, is an investigational non-opioid small molecule drug for the treatment of painful diabetic peripheral neuropathy. Patients suffering from this experience a painful burning or tingling sensation in areas such as the hands or feet and lower legs. This debilitating neuropathic pain substantially impairs quality of life. Given the ongoing opioid crisis with addiction to pain medication a growing problem, the non-opioid drug developed by Novaremed is a novel alternative treatment.

GEM’s investment represents the largest funding round for a Swiss startup this January, as was reported in a press release on the Startup.ch platform about the latest Swiss Venture Capital Report. Startups from the Basel Area also received the most financing of all regions.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
VectivBio raises 125 million US dollars in stock sale
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.